Count | |
| 4 | |
| 3 | |
| 1 | |
| 2 | |
| 2 | |
| 1 | |
| 1 | |
| 4 | |
Octreotide/*analogs & derivatives/diagnostic use/pharmacokinetics | 1 |
| 12 | |
| 36 | |
| 3 | |
| 4 | |
| 13 | |
| 1 | |
| 22 | |
| 25 | |
| 1 | |
| 6 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 7 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 5 | |
| 1 | |
| 1 | |
| 1 | |
Octreotide/*analogs & derivatives/*pharmacokinetics/therapeutic use | 1 |
| 1 | |
| 1 | |
Octreotide/administration & dosage/*pharmacology/therapeutic use | 1 |
Octreotide/administration & dosage/adverse effects/*therapeutic use | 1 |
| 1 | |
| 1 | |
| 3 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 7 | |
| 2 | |
| 4 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 4 | |
| 1 | |
| 2 | |
| 9 | |
| 3 | |
| 1 | |
| 1 | |
| 2 | |
| 59 | |
| 1 | |
| 8 | |
| 1 | |
| 3 | |
| 1 | |
| 2 | |
| 2 | |
| 2 | |
| 2 | |
| 1 | |
| 4 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 3 | |